Clinical, demographic and genetic features of patients with congenital heart disease : A single center experience
Objective: We aimed to evaluate the demographic and clinical characteristics of children with congenital heart disease (CHD) in a private pediatric cardiovascular genetics clinic in Istanbul from January 2016 to July 2018 and increase the awareness and emphasize the importance of genetic counseling in CHD. Patients and Methods: One hundred and seventeen patients (50 female, 67 male) from 3 days of age to 25 years of age in 17 months period ( January 2016 to July 2018) were retrospectively analyzed. Data included age, sex, echocardiography results, extracardiac features, genetic test results, consanguinity and any family member with heart disease. Pearson’s chi-squared test with 1 degree of freedom and 5% significance was used for correlations. Results: Consanguinity rate was 23.9%. Most common diagnosis was Tetralogy of Fallot (TOF) followed by atrial septal defect (ASD) and ventricular septal defect (VSD) equally. 30 patients had genetic testing which revealed a diagnosis in 36.6 % of the patients. 6 patients had DiGeorge, one had Renpenning,one had Kabuki syndrome. We had one NODAL, one MYH7 and one MYH6 variant. Conclusion: Genetic testing in CHD has a high diagnostic yield. Genetic counseling can help diagnostic, prognostic, and therapeutic and family planning decision making.
___
- [1] van der Linde D, Konings EEM, Slager MA, et al. Birth
prevalence of congenital heart disease worldwide. J Am Coll
Cardiol 2011; 58:2241-7. doi: 10.1016/j.jacc.2011.08.025
- [2] Jin SC, Homsy J, Zaidi S, et al. Contribution of rare inherited
and de novo variants in 2,871 congenital heart disease
probands. Nat Genet 2017; 49:1593-601. doi: 10.1038/ng.3970
- [3] Homsy J, Zaidi S, Shen Y, et al. De novo mutations in
congenital heart disease with neurodevelopmental and other
congenital anomalies. Science 2015; 350:1262-6. doi: 10.1126/
science.aac9396
- [4] Zaidi S, Choi M, Wakimoto H, et al. De novo mutations in
histone-modifying genes in congenital heart disease. Nature
2013; 498:220-3. doi: 10.1038/nature12141
- [5] Blue GM, Kirk EP, Giannoulatou E, et al. Advances in the
genetics of congenital heart disease. J Am Coll Cardiol 2017;
69:859-70. doi: 10.1016/j.jacc.2016.11.060
- [6] Geddes GC, Earing MG. Genetic evaluation of patients with
congenital heart disease. Curr Opin Pediatr 2018;30:707-13.
doi: 10.1097/MOP.000.000.0000000682
- [7] Hacettepe University Institute of Population Studies. 2018
Turkey Demographic and Health Survey. Hacettepe University
Institute of Population Studies, T.R. Presidency of Turkey
Directorate of Strategy and Budget and TÜBİTAK, Ankara,
Turkey 2019.
- [8] Miller DT, Adam MP, Aradhya S, et al. Consensus statement:
Chromosomal microarray is a first-tier clinical diagnostic test
for individuals with developmental disabilities or congenital
anomalies. Am J Hum Genet 2010; 86:749-64. doi: 10.1016/j.
ajhg.2010.04.006
- [9] Kung GC, Chang PM, Sklansky MS, Randolph LM. Hypoplastic
left heart syndrome in patients with Kabuki syndrome. Pediatr
Cardiol 2010; 31:138-41. doi: 10.1007/s00246.009.9554-7
- [10] Granados-Riveron JT, Ghosh TK, Pope M, et al. α-Cardiac
myosin heavy chain (MYH6) mutations affecting myofibril
formation are associated with congenital heart defects. Hum
Mol Genet 2010; 19:4007-16. doi: 10.1093/hmg/ddq315
- [11] Sabater-Molina M, Pérez-Sánchez I, Hernández del Rincón
JP, Gimeno JR. Genetics of hypertrophic cardiomyopathy: A
review of current state. Clin Genet 2018; 93:3-14. doi: 10.1111/
cge.13027
- [12] Hassel D, Dahme T, Erdmann J, et al. Nexilin mutations
destabilize cardiac Z-disks and lead to dilated cardiomyopathy.
Nat Med 2009; 15:1281-8. doi: 10.1038/nm.2037
- [13] Mohapatra B, Casey B, Li H, et al. Identification and functional
characterization of NODAL rare variants in heterotaxy and
isolated cardiovascular malformations. Hum Mol Genet 2009;
18:861-71. doi: 10.1093/hmg/ddn411
- [14] Botto LD, May K, Fernhoff PM, et al. A population-based
study of the 22q11.2 deletion: Phenotype, incidence, and
contribution to major birth defects in the population.
Pediatrics 2003; 112:101-7. doi:10.1542/peds.112.1.101
- [15] Cancrini C, Puliafito P, Digilio MC, et al. Clinical features
and follow-up in patients with 22q11.2 deletion syndrome. J
Pediatr 2014; 164:1475-80. doi: 10.1016/j.jpeds.2014.01.056
- [16] Pierpont ME, Brueckner M, Chung WK, et al. Genetic basis
for congenital heart disease: Revisited: A scientific statement
from the American Heart Association. Circulation 2018;
138:653-711. doi: 10.1161/CIR.000.000.0000000606
- [17] Goldmuntz E. 22q11.2 deletion syndrome and congenital
heart disease. Am J Med Genet C Semin Med Genet 2020;
184:64-72. doi: 10.1002/ajmg.c.31774
- [18] Morales-Demori R. Congenital heart disease and cardiac
procedural outcomes in patients with trisomy 21 and Turner
syndrome. Congenit Heart Dis 2017; 12:820-7. doi: 10.1111/
chd.12521
- [19] White BR, Rogers LS, Kirschen MP. Recent advances in our
understanding of neurodevelopmental outcomes in congenital
heart disease. Curr Opin Pediatr 2019; 31:783-8. doi: 10.1097/
MOP.000.000.0000000829